文献速递胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌肺寡转移立体定向放疗:国际回顾性多中心研究

Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-03-10

该国际多中心回顾性研究纳入35例接受SBRT治疗肺寡转移的前列腺癌患者,中位随访28.7个月,中位PFS为21.6个月,中位DMFS为32.4个月。未开始ADT的18例患者1年ADT无生存率为87.2%。SBRT对肺寡转移显示出良好肿瘤学结局,与骨和/或淋巴结寡转移SBRT报道相当。

要点

  • 35例前列腺癌肺寡转移患者接受SBRT,中位PFS为21.6个月,中位DMFS为32.4个月。
  • 未在SBRT前或同期开始ADT的18例患者,1年ADT无生存率为87.2%。
  • 单因素和多因素模型中未发现与PFS显著相关的参数。

核心结论

  • SBRT治疗前列腺癌肺寡转移提供良好的肿瘤学结局,与骨和/或淋巴结寡转移SBRT的报道相当。
  • 结果鼓励将肺寡转移患者纳入评估SBRT价值的临床试验。

研究设计与样本

  • 多中心回顾性研究,纳入35例接受SBRT治疗肺寡转移的前列腺癌患者,来自3个国家7个中心。
  • 97%的患者肺寡转移经PET-CT分期,51%经组织学活检确认。
  • 77%的患者为寡复发转移性疾病。

主要发现

  • SBRT前中位PSA为1.7 ng/mL [0.8, 3.0],SBRT后中位随访28.7个月。
  • 中位PFS为21.6个月 [95%CI: 21.6; NA],中位DMFS为32.4个月 [95%CI: 22.2-NA]。
  • 单因素和多因素模型中未发现与PFS显著相关的参数。
  • 未在SBRT前或同期开始ADT的患者(n=18),1年ADT无生存率估计为87.2% [71.9;100]。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of prostate cancer (PCa) patients with lung oligometastases remains unclear in the absence of published data. OBJECTIVE: The aim of this study was to evaluate the efficacy of Stereotactic Body Radiotherapy (SBRT) in this setting. DESIGN SETTING AND PARTICIPANTS: We conducted a multicenter retrospective study that included 35 PCa patients treated with SBRT for lung oligometastases in 7 centers across 3 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The efficacy was evaluated by the progression free-survival (PFS), defined as pre-SBRT PSA + 25 % or nadir PSA + 25 % and + 2 ng/mL or radiological progression if it occurred before biochemical progression. The local recurrence free-survival (LRFS), distant metastases free-survival (DMFS), Overall Survival (OS) and Androgen Deprivation Therapy free-survival were also assessed. Survival was estimated using the Kaplan Meier method. RESULTS: 35 patients were included with lung oligometastases staged with PET-CT for 97 % and histologically biopsy confirmed for 51 %. 77 % had an oligorecurrent metastatic disease. The median pre SBRT PSA was at 1.7 ng/mL [0.8, 3.0] and the median follow-up after SBRT was 28.7 months. The median PFS was 21.6 months [95 %CI: 21.6; NA] and the median DMFS was 32.4 months [95 %CI: 22.2-NA]. No parameters were significantly associated with PFS on the univariate and multivariate models.For patients who did not start ADT before or concomitantly with SBRT (n = 18), the 1-year ADT free-survival rate was estimated at 87.2 % [71.9;100]. CONCLUSIONS: SBRT for PCa lung oligometastases offers good oncological outcomes, comparable to those reported for bone and/or lymph node metastases SBRT. Our results encourage the inclusion of patients with lung oligometastatic disease in clinical trials designed to assess the value of SBRT. PATIENT SUMMARY: SBRT for prostate cancer lung oligometastases shows promising results, similar to treatments for bone or lymph node oligometastases.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rogé M, Bowden P, Conway P, et al. Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study. Clin Transl Radiat Oncol. 2025. PMID: 40162341. doi:10.1016/j.ctro.2025.100944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。